| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | WST | Common Stock | Options Exercise | $2.87M | +50K | +45.9% | $57.38* | 159K | Dec 5, 2022 | Direct | F1 |
| transaction | WST | Common Stock | Sale | -$1.6M | -6.75K | -4.24% | $236.95 | 152K | Dec 5, 2022 | Direct | F2, F3 |
| transaction | WST | Common Stock | Sale | -$2.24M | -9.41K | -6.18% | $237.67 | 143K | Dec 5, 2022 | Direct | F2, F4 |
| transaction | WST | Common Stock | Sale | -$1.51M | -6.31K | -4.42% | $238.83 | 136K | Dec 5, 2022 | Direct | F2, F5 |
| transaction | WST | Common Stock | Sale | -$2.58M | -10.8K | -7.88% | $239.70 | 126K | Dec 5, 2022 | Direct | F2, F6 |
| transaction | WST | Common Stock | Sale | -$2.33M | -9.68K | -7.7% | $240.73 | 116K | Dec 5, 2022 | Direct | F2, F7 |
| transaction | WST | Common Stock | Sale | -$266K | -1.1K | -0.95% | $241.46 | 115K | Dec 5, 2022 | Direct | F2, F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | WST | Stock Option (Right to Buy) | Options Exercise | $0 | -50K | -16.77% | $0.00 | 248K | Dec 5, 2022 | Common Stock | 50K | $57.38 | Direct | F9 |
| Id | Content |
|---|---|
| F1 | The shares reported were acquired by the Reporting Person from exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022. |
| F2 | This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. |
| F3 | The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $236.255 to $237.245, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| F4 | The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $237.255 to $238.21, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| F5 | The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $238.26 to $239.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| F6 | The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $239.26 to $240.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| F7 | The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $240.29 to $241.27, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| F8 | The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $241.33 to $241.56, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| F9 | This option is fully vested. |